Kimberly-Clark (KMB) M&A Announcement summary

Deal rationale and strategic fit

• The merger creates the largest pure-play consumer health and wellness company, combining highly complementary portfolios and global reach, and leveraging strengths in innovation, science, and commercial execution.

• Strategic logic centers on exposure to higher growth, higher margin health and wellness categories, driven by demographic trends and consumer health megatrends.

• The combined company will serve consumers at every life stage, enhancing category leadership, growth potential, and market penetration.

• Both companies share purpose-led, performance-driven cultures and a focus on science-backed innovation.

• The deal is the result of a strategic review and is seen as a generational value creation opportunity.

Financial terms and conditions

• Kenvue is valued at $48.7 billion enterprise value; shareholders receive $3.50 in cash and 0.14625 Kimberly-Clark shares per Kenvue share, totaling $21.01 per share.

• Acquisition multiple is 14.3x Kenvue's LTM adjusted EBITDA, or 8.8x including expected run-rate synergies.

• Kimberly-Clark shareholders will own 54% and Kenvue shareholders 46% of the combined company.

• Transaction expected to close in H2 2026, subject to shareholder and regulatory approvals.

• Cash component funded through balance sheet, new debt, and sale of a 51% interest in International Family Care and Professional business.

Synergies and expected cost savings

• Total expected synergies of $2.1 billion EBITDA: $1.9 billion from cost and up to $500 million from revenue, with $300 million reinvested.

• Cost synergies to be realized within three years post-close; revenue synergies within four years.

• One-time integration costs projected at $2.5 billion over two years.

• Synergies identified across procurement, manufacturing, sales, marketing, and G&A.

• Conservative synergy targets benchmarked against similar CPG and healthcare deals.